The ABPI welcomes this important report from Lord Warner’s Short Life Commission into the future of the commissioning and delivery of specialised services within England.
23 May 2016 Posted in By Paul Catchpole
Commenting on the report, Dr Paul Catchpole, Director of Value and Access at the ABPI said:
"This report, taken together with the recent National Audit Office report and imminent publication of the Accelerated Access Review is very timely. In particular the recognition of the need for national standards - locally delivered and supported by clear accountability – and the publication of robust, consistent and regular outcomes and performance data.
"NHS England now has a fantastic opportunity to refocus and re-invigorate the commissioning and delivery of specialised services for the benefit of patients, the NHS and wider society.
"New research and innovative treatments are leading to many new therapies - the majority of which fall within the specialised remit - offering new treatments and cures which only a few years ago were not dreamed off.
"We recognise the challenges these new treatments bring, but stand ready and very willing to with work with NHS England and Trusts so that together we can bring these new treatments to the clinical frontline as quickly as possible. It is of vital importance that, together, we get this right."
The ABPI welcomes this important report from Lord Warner's Short Life Commission into the future of the commissioning and delivery of specialised services within England.
In particular the ABPI supports its main tenet of national standards, locally delivered and supported by clear accountability, and the publication of robust, consistent and regular outcomes and performance data.
The report also highlights the fundamental role that specialised services have in the uptake of innovation and innovative new treatments – for the benefit of patients, the NHS and the wider economy.
It recommends significant developments are required in terms of both commissioning and payment systems along with much greater integration of providers across specialised care networks.
The ABPI supports the direction set out in the report of moving towards outcomes based, multi-year funding models underpinned by better data – supporting a system that recognises the value of innovative medicines in terms of improving patient outcomes and wider benefits to the NHS and society.
The reports also rightly recommends that there should be clear cut, annual accountability to Parliament and the public for the large sums of public money spent on specialised services, supported by greater transparency across the system. This reinforces the recent NAO report and echo's the ABPI's own call for greater transparency of process, decision making and accountability. Without this, public and stakeholder confidence is undermined.
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday):
+44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends):
+44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.